C-C motif chemokine receptor 2 and C-C motif chemokine receptor 5 (CCR2/CCR5)

C-C motif chemokine receptor 2 (CCR2) and C-C motif chemokine receptor 5 (CCR5) are structurally related G protein-coupled receptors (GPCRs) that play pivotal roles in the immune system by mediating the migration and activation of leukocytes, particularly monocytes, macrophages, and T cells, to sites of inflammation [1, 2, 5]. CCR5 is well-known as a primary co-receptor for HIV-1 entry into host cells, while CCR2 is the main receptor for CCL2 (MCP-1), a key driver of monocyte recruitment from the bone marrow [2, 5, 12]. Dual targeting of CCR2 and CCR5 has emerged as a therapeutic strategy to address complex inflammatory and fibrotic diseases, such as nonalcoholic steatohepatitis (NASH), liver fibrosis, and atherosclerosis, where both receptors contribute to disease progression [2, 3, 7, 10]. Drugs like cenicriviroc act as dual antagonists to block the infiltration of inflammatory cells and reduce tissue damage [3, 14]. Despite promising preclinical data, clinical success has been mixed, highlighting the complexity of the chemokine signaling network and the potential for functional redundancy [1, 4, 6]. These receptors are also implicated in other conditions, including multiple sclerosis, rheumatoid arthritis, and certain cancers, where they modulate the tumor microenvironment [2, 6, 10]. Therapeutic development continues to focus on optimizing the balance between potent receptor blockade and maintaining necessary immune surveillance [1, 8].

Other names

C-C motif chemokine receptor 2C-C motif chemokine receptor 5CD192CD195CKR2CKR5MCP-1 receptorRANTES receptorCCR2/5

Dual antagonism of CCR2 and CCR5 receptors, which inhibits the binding of ligands such as CCL2 and CCL5, thereby blocking the recruitment of inflammatory monocytes and T cells to tissues and preventing CCR5-mediated viral entry.